# Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

> **NCT04853927** · PHASE3 · WITHDRAWN · sponsor: **Applied Biology, Inc.**

## Conditions studied

- Covid19
- SARS (Severe Acute Respiratory Syndrome)

## Interventions

- **DRUG:** Proxalutamide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04853927
- **Lead sponsor:** Applied Biology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-02-08
- **Primary completion:** 2021-10-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor to focus on hospitalised patients
- **Last updated:** 2022-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04853927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04853927, "Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04853927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*